A next generation cancer therapy helps immune cells detect, and destroy cancer cells. This therapy works by evading two mechanisms that cancer cells use to evade macrophages, cells whose job it is to eat and destroy cancerous cells.

“The researchers [at Brigham and Women’s Hospital] tested the supramolecular therapeutic in animal models of aggressive forms of breast cancer and skin cancer, comparing their drug directly with a drug currently available in the clinic. Mice that were untreated formed large tumors by Day 10. Mice treated with currently available therapies showed decreased tumor growth. But mice treated with the new supramolecular therapy had complete inhibition of tumor growth. The team also reported an increase in survival and a significant reduction in metastatic nodes.”

This treatment is skill in the testing phases but it hold potential for future applications.

Read More.

The Eagle Biosciences Humanized Anti HER-2 ELISA Assay Kit detect levels of Trastuzumab (Herceptin) in human serum and plasma.

What is HER-2?

The Human Epidermal Growth Factor Receptor 2 gene (HER-2) can play a role in the development of breast cancer. This gene codes for a protein that are receptors on breast cells and helps the cell grow and divide normally. When regulation of the HER-2 gene gets disrupted or too many copies of the HER-2 gene are present in the cell, this can lead to an increased amount of the HER-2 protein on the cell surface. This causes the cell to start growing out of control and can develop into a tumor. Trastuzumab (Herceptin) is a drug that blocks the ability of the HER-2 protein on the surface of cells to receive chemical signals telling the cell to grow. This can slow or stop the growth of these breast cells and can also signal the immune system that these cells need to be destroyed. Measuring the levels of this drug in serum or plasma are important for evaluating the effectiveness of drug therapy.

Key Advantages of EagleBio’s Anti HER-2 ELISA

  • Excellent Specificity
  • High Sensitivity
  • Precise results under 2 hours

Eagle announces the introduction of an Intact MMAF ADC ELISA Assay Kit to its line of existing Antibody Drug Kits. This Intact MMAE Kit is the first of its kind, allowing for the measurement of conjugated antibody in a variety of sample types.

What is MMAF (Monomethyl auristatin F)?

MMAF is a new type of targeted therapy for cancer treatment. It is a synthetic antineoplastic agent that is a toxic compound; when linked to a monoclonal antibody (mAb) it gets directed to cancer cells. This drug treatment targets tumors and inhibits their growth by blocking the polymerization of tubulin in the cell. Measuring circulating specific ADC’s is importatnt for pre-clinical and clinical studies for the discovery of unique, targeted, safer, effective cancer treatments.

Key Advantages to Eagle Biosciences’s Antibody Drug Conjugates Assays:

  • Excellent Sensitity
  • Simple Procedure
  • Wide Dynamic Range
  • Quick Results: Under 3 hours
  • Versatile: multiple sample types and species

Related Kits:

MMAF Antibody Drug Conjugate (ADC) ELISA Assay Kit

MMAE Antibody Drug Conjugate (ADC) ELISA Assay Kit

Intact MMAE ADC ELISA Assay Kit

image by Bru-nO pixaby

A women with late stage breast cancer, given less than five years to live, participates in an experimental T-cell immunotherapy. After several rounds of failed chemotherapy, this experimental trial used the women’s own immune cells to target and fight off the tumor, leaving her cancer free for two years. 

This new therapy, though still experimental and expensive, shows a promising outlook for helping other patients with metastatic breast cancer, and other cancers such as prostate and ovarian cancer.

Read More. 

[1]. Sample, Ian, and Jessica Glenza. “Doctors Hail World First as Woman’s Advanced Breast Cancer Is Eradicated.” The Guardian, Guardian News and Media, 4 June 2018.

Eagle announces the introduction of an Intact MMAE ADC ELISA Assay Kit to its line of existing Antibody Drug Kits. This Intact MMAE Kit is the first of its kind, allowing for the measurement of conjugated antibody in a variety of sample types. 

What is MMAE (Monomethyl auristatin E)?

MMAE is a new type of targeted therapy for cancer treatment. It is a synthetic antineoplastic agent that is a toxic compound; when linked to a monoclonal antibody (mAb) it gets directed to cancer cells. This drug treatment targets tumors and inhibits their growth by blocking the polymerization of tubulin in the cell. Measuring circulating specific ADC’s is importatnt for pre-clinical and clinical studies for the discovery of unique, targeted, safer, effective cancer treatments.

Key Advantages to Eagle Biosciences’s Antibody Drug Conjugates Assays:

  • Excellent Sensitity
  • Simple Procedure
  • Wide Dynamic Range
  • Quick Results: Under 3 hours
  • Versatile: multiple sample types and species

Related Kits:

MMAE Antibody Drug Conjugate (ADC) ELISA Assay Kit

image credit: https://www.nature.com/news/

Personalized Cancer Vaccines Show Glimmer of Success

In two small clinical trials, led by Catherine Wu a the Dana-Farber Institute of Cancer, six people with skin cancer showed a positive immune response after the injection of a personalized cancer vaccine engineered specifically for their tumors. 

Read More.

Ledford, Heidi. “Personalized cancer vaccines show glimmers of success.” Nature News. Nature Publishing Group, 05 July 2017. Web. 06 July 2017.

        image credit: https://corporate.dukehealth.org

DURHAM, N.C. — The chemical bisphenol A, or BPA, appears to aid the survival of inflammatory breast cancer cells, revealing a potential mechanism for how the disease grows, according to a study led by researchers in the Department of Surgery at Duke University School of Medicine and the Duke Cancer Institute.

Read More


Source: (https://corporate.dukehealth.org)


A recent research study focused on screening more than 1,000 drugs already approved for various therapeutic indications. The objective was to find which drugs are capable of inhibiting the protein involved in the pancreatic cancer development process, Nupr1.

“Trifluoperazine, a molecule long used to treat anxiety has been found to interfere with the activity of a protein involved in the pancreatic cancer development process. A study by the Nanotechnology Institute of CNR, unit of Rende, in collaboration with a team of French and Spanish researchers, identified the molecule.

Pancreatic cancer is one of the most lethal tumors. Up until now, the only drugs available to fight it are generic chemotherapy treatments.”  Read More

Source: (https://reliawire.com/trifluoperazine-pancreatic-tumors/)

Metformin Plus Syrosingopine Effectively Combats Cancer Cells

Bengtsson, M.  Metformin Plus Syrosingopine Effectively Combats Cancer Cells. December 27, 2016 Retrieved from: www.reliawire.com.

A combination of a diabetes medication and an antihypertensive drug effectively fights cancer cells, according to a team of researchers at the University of Basel. They also report that specific cancer cells respond to this combination of drugs.”   Read More


Source: (https://reliawire.com/metformin-syrosingopine-cancer/)




Image Credit:ZOSIA ROSTOMIAN/BERKELEY LAB

Study finds potential new biomarker for cancer patient prognosis

“To treat or not to treat? That is the question researchers at the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) hope to answer with a new advance that could help doctors and their cancer patients decide if a particular therapy would be worth pursuing”  Read More

Source:(https://www.eurekalert.org/pub_releases/2016-08/dbn. ).

.